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Abstract Skeletal muscle is an organ involved in whole body
movement and energy metabolism with the ability to dynam-
ically adapt to different states of (dis-)use. At a molecular level,
the peroxisome proliferator-activated receptor γ coactivators 1
(PGC-1s) are important mediators of oxidative metabolism in
skeletal muscle and in other organs. Musculoskeletal disorders
as well as obesity and its sequelae are associated with PGC-1
dysregulation in muscle with a concomitant local or systemic
inflammatory reaction. In this review, we outline the function
of PGC-1 coactivators in physiological and pathological con-
ditions as well as the complex interplay of metabolic dysreg-
ulation and inflammation in obesity with special focus on
skeletal muscle. We further put forward the hypothesis that,
in this tissue, oxidative metabolism and inflammatory process-
es mutually antagonize each other. The nuclear factor κB
(NF-κB) pathway thereby plays a key role in linkingmetabolic
and inflammatory programs in muscle cells. We conclude this
review with a perspective about the consequences of such a
negative crosstalk on the immune system and the possibilities
this opens for clinical applications.
Keywords Skeletal muscle . Metabolism .Metabolic
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Introduction
Obesity has become a global epidemic, and a large number of
deaths can be attributed to obesity-related disorders
commonly known as the “metabolic syndrome.” Understand-
ing the molecular mechanisms underlying this syndrome is
crucial to be able to develop appropriate treatment strategies
and improve quality of life of patients. Skeletal muscle is
important in glucose homeostasis as a large part of blood
glucose is taken up into this tissue, stored as glycogen, or
used as substrate. Skeletal muscle insulin resistance is thus
detrimental as it disturbs whole body glucosemetabolism. The
development of insulin resistance is closely linked to inflam-
mation, which has been studied extensively in white adipose
tissue. Macrophages and other cells of the immune system
interact with cells of the resident tissue to promote or restrain
inflammatory reactions. This fosters or impedes the genesis of
insulin resistance, respectively. In skeletal muscle, these pro-
cesses and their interdependence have just started to be
elucidated.
PGC-1 coactivators are transcriptional coregulators that
facilitate expression of an oxidative metabolic program in
energy-demanding organs including skeletal muscle, in par-
ticular, in adaptation to endurance training. Many skeletal
muscle pathologies, for example, muscle wasting, are associ-
ated with PGC-1 repression and accompanied by inflamma-
tory reactions in muscle tissue. PGC-1 downregulation has
also been observed in skeletal muscle of diabetic patients that
display higher levels of pro-inflammatory cytokines both in
muscle and blood, a situation that is recapitulated in mice that
lack PGC-1α. Inversely, exercise is known to promote anti-
inflammatory effects and PGC-1 coactivators recently have
been shown to have anti-inflammatory properties in vitro.
In the current review, we therefore examine the influence of
inflammation on PGC-1 coactivators and vice versa focusing
on skeletal muscle. We provide thorough background infor-
mation on all the relevant areas including skeletal muscle
physiology and pathology, PGC-1 coactivator regulation and
function, and the molecular basis of inflammatory reactions.
We then explore how oxidative metabolism and inflammatory
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processes are linked providing evidence for a mutual, negative
regulation. This antagonism has far-reaching consequences
both for muscle and immune cells, positioning skeletal muscle
at the crossroad of metabolic and inflammatory processes.
Skeletal muscle
Skeletal muscle structure and function
The human body contains different types of muscle, mainly
skeletal muscle, cardiac muscle, and smooth muscle that all
have the ability to contract. While cardiac and smooth muscle
contraction is involuntary, skeletal muscle contraction can be
controlled deliberately as it contributes fundamentally to lo-
comotion and posture.
To fulfill these purposes, skeletal muscle is attached to the
bone by tendons, enveloped by a layer of connective tissue
(the epimysium) and organized in several functional units.
The largest unit is the muscle bundle. Each skeletal muscle
comprises several bundles, so-called fasciculi, which are con-
fined by the perimysium, another layer of connective tissue.
The second functional unit is the myofiber, a postmitotic,
syncytial muscle cell, itself lined by connective tissue (the
endomysium). Multiple myofibers run in parallel to form a
bundle. Each myofiber contains numerous myofibrils, the
smallest functional unit of skeletal muscle. Myofibrils are
linear sequences of sarcomers, which are the fundamental
contractile element of muscle cells. Under the microscope,
these sarcomere repeats appear as distinct bands giving skel-
etal muscle its unique, striated pattern. At a molecular level,
sarcomers are composed of the interdigitating myofilaments
myosin and actin, which contract by sliding along each other
and thereby shorten the muscle [1].
Skeletal muscles are innervated by motor neurons, which
originate in the spinal cord. The synapse between motor
neuron and muscle constitutes the neuromuscular junction.
One motor neuron and all muscle fibers that are innervated
by this neuron are called a motor unit. All fibers of a motor
unit always contract in conjunction upon excitation of the
innervating motor neuron. This excitation manifests in an
action potential which leads to release of the neurotransmitter
acetylcholine into the synaptic cleft at the neuromuscular
junction. Postsynaptically, acetylcholine binds to its receptor,
a ligand-gated ion-channel, and evokes an end plate potential
by depolarization. This potential propagates along the fiber
membrane (sarcolemma) which has deep invaginations (trans-
verse tubules) harboring voltage-gated dihydropyridine recep-
tors. These receptors in turn activate ryanodine receptors in
the adjacent sarcoplasmic reticulum (SR) leading to a release
of calcium from this compartment. Increased intracellular
calcium concentrations finally initiate contraction. The close
proximity of dihydropyridine receptors in the sarcolemma of
transverse tubules and ryanodine receptors in the SR enables
excitation–contraction coupling [1].
Contraction requires the binding of myosin to actin fila-
ments. In the basal state, the binding sites (active sites) are
however masked by the troponin–tropomyosin complex, thus
hindering interactions. Binding of calcium to troponin ex-
poses the active sites and enables myosin heads to form
cross-bridges which subsequently move, hence the sliding of
the myofilaments against one another. The cross-bridges are
released by binding of ATP allowing another cycle of con-
traction. Contraction ends when calcium is pumped back to
the SR and no further actin-myosin interactions occur [1].
Metabolic characteristics of skeletal muscle
Myosin filaments in skeletal muscle contain six subunits, two
heavy chains, and four light chains, whereby different types of
myosin heavy chains (MHC) can be distinguished. They vary
in their contractile characteristics and are prototypical for dif-
ferent types of muscle fibers, which are adapted to different
kinds of contraction. Type I or slow fibers that contain MHC I
contract with low maximal force but are highly resistant to
fatigue while type II or fast fibers that contain MHC II fatigue
rapidly but are able to produce a high maximal force. Type I
fibers appear red due to a high level of vascularization while
type II fibers appear white. The latter can be further subdivided
into type IIa (moderately fast), type IIx (intermediate), and type
IIb (very fast) fibers. According to their contraction properties,
the various fiber types primarily rely on different metabolic
pathways as energy source: While type I and IIa fibers are
oxidative, type IIx and IIb fibers are glycolytic [1].
Glycolytic fibers mainly metabolize glucose, which is taken
up into muscle cells by glucose transporters (GLUT), some of
which translocate to the membrane upon higher energy de-
mand. In the cytosol, glucose is then converted into pyruvate
by glycolysis producing ATP via substrate-level phosphoryla-
tion. As glycolytic fibers contain fewmitochondria, pyruvate is
further transformed anaerobically into lactic acid, recovering
the pool of NAD+, an essential cofactor of glycolysis [2]. This
process enables very fast supply of energy for intensive bursts
of work, however only for limited periods of time. Type II
muscle fibers are thus typical for strength athletes.
At the other end of the spectrum, oxidative fibers contain a
high number of mitochondria, which are the main site of
aerobic energy production. The mitochondrial matrix harbors
enzymes of fatty acid β oxidation and the citric acid cycle
while the mitochondrial inner membrane comprises the com-
ponents of the electron transport chain. Fatty acids are the
main energy substrate of oxidative fibers besides glucose.
They are taken up into muscle cells by fatty acid translocase
CD36, activated in the cytosol, and shuttled into mitochondria
as acylcarnitines. Fatty acidβ oxidation then generates acetyl-
CoA that is fed into the citric acid cycle producing NADH,
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which serves as electron donor of the electron transport chain
(complex I-IV) with oxygen being the final acceptor. The
energy liberated during the electron passage is stored as an
electrochemical proton gradient across the inner mitochondri-
al membrane and ultimately dissipated by the ATP synthase
that drives aerobic ATP production [2].
ATP fuels muscle contraction because it enables the release
of myosin-actin interaction which is a prerequisite for the
subsequent contraction cycle whereas ATP depletion results
in muscle fatigue and the inability to sustain performance. In
addition, ATP is required for various other processes that are
important for muscle contraction, for example, ATP-driven re-
uptake of calcium into the SR. The availability and utilization
of energy substrates is therefore vital for continuous contrac-
tion. As oxidative metabolism in type I muscle fibers is well-
adapted to prolonged periods of intermediate workloads, these
fibers are characteristic for endurance athletes.
Obesity-related changes in skeletal muscle
Skeletal muscle is the main site of glucose disposal in the body
and therefore contributes substantially to whole-body glucose
homeostasis. In metabolic diseases, glucose homeostasis be-
comes dysregulated, resulting in hyperglycemia due to elevat-
ed levels of hepatic gluconeogenesis and diminished levels of
glucose uptake into target tissues like skeletal muscle and fat.
The deficit in glucose uptake stems from progressive insulin
resistance of target tissues that precedes the exhaustion of
insulin-producing pancreatic β cells in type 2 diabetes [3].
Overnutrition raises free fatty acid levels in the circulation.
Target cells including myocytes are unable to deal with the
constant oversupply of lipids as it exceeds their capacities to
oxidize fatty acids in mitochondria or store them as triglycer-
ides. Therefore, lipid metabolites like diacylglycerol and
ceramides accumulate within the cell. These lipids activate
serine kinases, for example, protein kinase C that may phos-
phorylate insulin receptor substrate 1 (IRS1) at inhibitory
serine residues [3]. In healthy muscle, IRS1 is phosphorylated
at tyrosine residues upon insulin binding to its receptor. This
in turn initiates phosphatidylinositol 4,5-bisphosphate 3-
kinase (PI3K) and subsequent protein kinase B (PKB)/Akt
activation, which finally phosphorylates GLUT4 leading to
membrane translocation and glucose uptake into the cell.
Inhibitory IRS1 serine phosphorylation in obesity blunts this
signaling cascade as it prevents the required tyrosine phos-
phorylation events and therefore causes insulin resistance [3].
Indeed, intramyocellular lipid levels strongly correlate with
insulin resistance. In non-diabetic subjects, insulin resistance
initially may be compensated for by hyperinsulinemia in order
to preserve normal glucose tolerance. Aggravated insulin
resistance and β cell dysfunction then mark the transition to
overt type 2 diabetes where glucose tolerance is lost.
Mitochondria produce reactive oxygen species (ROS) as
byproducts of cellular respiration when oxygen is reduced
prematurely. The excess of fatty acids in skeletal muscle of
obese patients and the associated overload of mitochondria
leads to higher rates of ROS generation. Together with an
insufficient ROS detoxification, this creates an environment
of permanent oxidative stress [4]. Apart from the direct dam-
age that ROS inflict upon macromolecules like DNA, pro-
teins, and lipids, oxidative stress also activates a number of
cellular stress pathways including c-Jun N-terminal kinases
(JNK) and p38/mitogen-activated protein kinases (MAPK)
[4]. These serine kinases directly target IRS1 at inhibitory
residues and thus bring about skeletal muscle insulin resis-
tance. Furthermore, the nuclear factor κB (NF-κB) pathway is
redox-sensitive. Activation of JNK, p38/MAPK, and NF-κB
additionally induces transcription of inflammatory factors that
substantially contribute to the development of insulin resis-
tance. The exact role of inflammation in obesity and type 2
diabetes will be outlined below.
The endoplasmic reticulum (ER) is responsible for synthe-
sis, correct folding, and secretion of proteins within the cell. It
also plays an important role in calcium homeostasis, which is
especially relevant in myocytes as calcium release from the
SR initiates contraction. ER stress arises when this organelle is
overburdened. Consequently, the unfolded protein response
(UPR) acts as adaptive mechanism to resolve ER stress by
reducing protein synthesis, increasing protein degradation and
ER folding capacities through higher chaperone levels [5]. If
chronically active, the UPR also induces NF-κB and JNK
signaling, which both cause transcription of inflammatory
factors and inhibitory IRS1 phosphorylation events leading
to insulin resistance. ER stress may also heighten ROS levels,
which again has a negative influence on insulin sensitivity.
The accumulation of lipid derivatives in skeletal muscle of
obese patients leads to considerable ER stress, which is also
evident in vitro when treating muscle cells with palmitate [6,
7]. Tunicamycin-induced, profound ER stress dampens insu-
lin action in myocyte cultures by evoking JNK and mamma-
lian target of rapamycin (mTOR)/S6 kinase-1 (S6K1) signal-
ing, which both target IRS1 serine residues [6]. Whether the
same pathways are active in muscle cells treated with palmi-
tate is less clear, and the contribution of ER stress to the
development of insulin resistance under these conditions re-
mains controversial [7].
The PGC-1 family
Molecular characteristics of PGC-1 coactivators
Transcription is a tightly regulated process that involves the
binding of transcription factors to response elements in the
promoter region of target genes. Those transcription factors
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subsequently attract chromatin remodeling enzymes and the
RNA polymerase complex to the promoter in order to initiate
transcription. Transcriptional activation is further fine-tuned
by coregulators that either facilitate (coactivators) or hinder
(corepressors) initiation.
The peroxisome proliferator-activated receptor (PPAR) γ
coactivator 1 (PGC-1) family comprises three members, PGC-
1α, PGC-1β, and PGC-1-related coactivator (PRC) that all act
as transcription coactivators. Their common structure features
an N-terminal activation domain (AD), one or several LXXLL
or LLXXL motifs (where L is leucine and X is any amino
acid) that represent the interface for nuclear receptor (NR)
binding, a serine-rich or arginine-/serine-rich domain, and a
C-terminal RNA recognition and splicingmotif (Fig. 1). PGC-
1α and PGC-1β also contain an inhibitory domain of about
200 amino acids adjacent to the AD. Two glutamine-rich
domains are further characteristic for PGC-1β, while PRC
has a unique proline-rich domain (Fig. 1).
The PGC-1 coactivators do not harbor a DNA binding
domain but interact with specific transcription factors and
NRs. PGC-1α was originally discovered as cofactor of
PPARγ and thyroid hormone receptor (TR) [8]. Subsequent
studies identified most NRs as PGC-1α binding partners,
including PPARα, PPARβ/δ, liver X receptor (LXR),
farnesoid X receptor (FXR), vitamin D receptor (VDR), con-
stitutive androstane receptor (CAR), pregnane X receptor
(PXR), estrogen receptor α (ERα), estrogen-related receptor
α (ERRα) and ERRγ, glucocorticoid receptor (GR), hepatic
nuclear factor 4 α (HNF4α), and retinoid X receptor (RXR)
[9–20]. This interaction can be either constitutive or ligand-
dependent, and indeed, human PGC-1α was identified in a
screen for steroid-responsive genes [21]. PGC-1α is further
able to coactivate a number of non-NR transcription factors
like forkhead box protein O1 (Fox O1), FoxO3a, nuclear
respiratory factor 1 (NRF1), myocyte-specific enhancer factor
2A (MEF2A), and MEF2C [22–26]. They bind PGC-1α via
domains that are distinct from the LXXLL motifs.
PGC-1β interacts with the NRs PPARα, ERα, ERRα, and
ERRγ; the transcription factors sterol regulatory element-
binding protein 1a (SREBP1a) and SREBP1c; and FoxA2
[27–33]. Finally, PRC is able to potentiate ERRα- and
NRF1-dependent transcription [34, 35].
Mechanistically, after binding to NRs or transcription fac-
tors, the PGC-1 coactivators act as recruitment platform for
protein complexes that further boost transcription. The details
of this assembly have been explored meticulously for PGC-
1α: The AD interacts with the histone acetyltransferases
(HATs) steroid receptor-1 (SRC-1) and cyclic AMP response
element-binding protein (CREB) binding protein (CBP)/
p300, which mediate decondensation of chromatin [36].
BRG-1-associated factor 60a (BAF60a) tethers the chromatin
remodeling switch/sucrose nonfermentable (SWI/SNF) com-
plex to a central stretch within the PGC-1α protein, while the
C-terminal region binds the TR-associated protein (TRAP)/
vitamin D receptor-interacting protein (DRIP) or Mediator
complex that directly associates with the basal transcription
machinery and thus contributes to preinitiation complex for-
mation [37, 38].
The positive effect of PGC-1 coactivators on transcription
can be abrogated by nuclear corepressors that compete for
binding sites on NRs and thus displace the coactivators.
Examples include small heterodimer partner (SHP), SHP
interacting leucine zipper protein (SMILE), and dosage-
sensitive sex reversal adrenal hypoplasia congenital critical
region on X chromosome, gene 1 (DAX-1) [39–42]. Beyond
the initiation of RNA polymerization, PGC-1α is also impli-
cated in RNA processing via the RNA recognition and splic-
ing domain at the C terminus [43].
Several isoforms of PGC-1 coactivators are currently
known (Fig. 1). Alternative splicing gives rise to NT-PGC-
1α (amino acids 1–270), and to PGC-1β-a and PGC-1β-b
(differing in exon 11) while alternative promoter usage gen-
erates PGC-1β-1 (comprising exon 1a) and PGC-1β-2 (com-
prising exon 1a′ and exon 1b) [44, 45]. PGC-1α can also be
transcribed from either the proximal or the alternative promot-
er (about 13 kb upstream) resulting in expression of PGC-1α-
a/PGC-1α1 (proximal promoter, exon 1), PGC-1α-b/PGC-
1α2 (exon 1b″), PGC-1α-c/PGC-1α3 (exon 1b′), and PGC-
1α4 (exon 1b″), the last three all originating at the alternative
promoter [46–48] (Fig. 1). In skeletal muscle, PGC-1α-b/
PGC-1α2 and PGC-1α-c/PGC-1α3 are involved in adapta-
tions to endurance exercise while PGC-1α4 mediates a hy-
pertrophic response upon resistance training [47, 48].
Regulation of PGC-1α activity
As PGC-1 coactivators are potent inducers of transcription,
their activity and expression levels are tightly controlled with-
in the cell. Post-translational modifications (PTMs) and intra-
cellular signaling events are by far best-studied for PGC-1α
and will be outlined in the following sections.
Different transcription factors control the synthesis of
PGC-1α mRNA: CREB is a potent inducer of PGC-1α ex-
pression in different tissues and binds to CRE in the promoter
region of PGC-1α when phosphorylated by protein kinases
[49]. In skeletal muscle, exercise-mediated calcium release
activates calcium/calmodulin-dependent protein kinase type
IV (CaMK IV), which targets CREB and thereby augments
PGC-1α transcription [50].
MEF2C and MEF2D are able to bind to MEF2 sites in the
PGC-1α promoter and elevate PGC-1α expression. Free,
cytosolic calcium not only activates CaMK IV in skeletal
muscle but also the phosphatase calcineurin A (CnA), which
boost the activities of MEF2C and MEF2D. These transcrip-
tion factors are bound and coactivated by PGC-1α at its own
promoter constituting a positive, autoregulatory feed-forward
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Fig. 1 Schematic representation of the murine PGC-1 family members
and transcript variants. AD , activation domain; ID , inhibitory domain;
RS, arginine-/serine-rich domain; RRM , RNA recognition and splicing
motif; S , serine-rich domain; P, proline-rich domain; L , LXXLL or
LLXXL motif; Q , glutamine-rich domain 1 and 2. Numbers indicate
amino acid positions and refer to RefSeq transcripts; different N-terminal
amino acid sequences corresponding to a different exon 1 and arising
from alternative promoter usage are indicated in green and blue; an
asterisk indicates additional C-terminal amino acids that are not shared
by all splice variants [27, 29, 35, 44–48, 318]
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loop [50]. Exercise also activates p38/MAPK, which partici-
pates in PGC-1α transcriptional regulation at two places: p38/
MAPK phosphorylates both MEF2C/D and activating tran-
scription factor 2 (ATF2), thereby facilitating their binding to
the PGC-1α promoter and further boosting transcription [51,
52]. Direct PGC-1α phosphorylation will be discussed below.
As a sensor of low energy levels in the cell, AMP-activated
protein kinase (AMPK) is also activated upon muscle con-
traction and promotes PGC-1α expression [53]. Another
autoregulatory loop has been described for PPARβ/δ: PGC-
1α heightens both PPARβ/δ and its own expression by
coactivating this NR at the PGC-1α promoter [54]. PPARα
and PPARγ are part of similar autoregulatory mechanisms in
other organs, which therefore appear to be a common strategy
in the induction of PGC-1α expression [54, 55].
Reciprocally, transcription of the PGC-1α gene can be
inhibited by several factors. In hepatocytes, insulin-
stimulated Akt targets FoxO1, which as a result dissociates
from the PGC-1α promoter [56]. The recruitment of chroma-
tin remodeling enzymes and transcription corepressors to the
promoter also influences PGC-1α expression levels. Binding
of histone deacetylases (HDACs) like HDAC5 to MEF2
compromises transcription as does the presence of SHP and
nuclear corepressor 1 (NcoR1) [57–59]. A more general
mechanism of repression is hypermethylation of non-CpG
nucleotides in the PGC-1α promoter, which is caused by
DNA methyltransferase 3B (DNMT3B) [60].
The second important aspect defining the transcriptional
coactivator potential of PGC-1α is the modulation of PTMs
that regulate protein stability and the binding affinity to tran-
scription factors. A number of PTMs of PGC-1α have been
reported, including phosphorylation, acetylation, methylation,
GlcNAcylation, sumoylation, and ubiquitination.
Kinases target several serine and threonine residues within
the PGC-1α protein. AMPK- and p38/MAPK-dependent
phosphorylation stabilizes PGC-1α and decreases the interac-
tion with the repressor p160 myb binding protein (p160 mbp)
[53, 61, 62]. As both kinases also affect PGC-1α transcription,
they have a dual effect involving an acute (phosphorylation)
and a more sustained (expression) response. Similarly, PKA
phosphorylates NT-PGC-1α, a short transcript variant of
PGC-1α, and at the same time CREB, again constituting a
dual, positive mode of action [63]. Akt and glycogen synthase
kinase 3β (GSK3β) both mediate inhibitory PGC-1α phos-
phorylation events [64, 65]. Prior negative phosphorylation is
also required for polyubiquitination of PGC-1α, which targets
the protein for proteasomal degradation [66].
The acetylation status of PGC-1α further affects its activity.
Acetyltransferase general control of amino acid synthesis 5
(GCN5) acetylates PGC-1α at multiple lysine residues, thus
rendering it inactive due to relocalization to nuclear foci, while
NAD+-dependent protein deacetylase sirtuin 1 (Sirt1)
removes these inhibitory acetyl residues [67–69]. As Sirt1
and AMPK are both sensors of cellular energy status, they
act in concert to coordinately activate PGC-1α [70].
SUMOylation of PGC-1α does not change its subcellular
localization or stability, but presumably facilitates interaction
with receptor-interacting protein 140 (RIP140), a known re-
pressor of PGC-1α [71, 72]. Finally, O -linked β-N -
acetylglucosylation and arginine methylation of PGC-1α con-
tribute to sustained transcription activity of this coactivator
[73, 74].
The multitude of PTMs is a result of the complex signaling
network that converges on PGC-1α. Uncovering mutual in-
fluences and resolving the chronology of events in different
organs in greater detail remains to be done.
Role of PGC-1 coactivators in oxidative metabolism
and skeletal muscle function
PGC-1α orthologs are present in all vertebrate species, with
95 % sequence homology between mouse and human, and a
high degree of conservation in the AD and NR interaction
domain [21, 75]. In Drosophila , the PGC-1 homologue
spargel is essential for mitochondrial gene expression and
spargel mutants display respiration defects [76]. This funda-
mental role of PGC-1 coactivators in cellular respiration is
conserved across species, redundant between all three family
members and important in all tissues that express PGC-1
coactivators. PGC-1α and PGC-1β are primarily enriched in
organs with high oxidative capacity like skeletal muscle,
heart, brown adipose tissue (BAT), kidney, and brain whereas
PRC is found ubiquitously [8, 27, 35]. Hence, it appears that
the coordination of oxidative metabolism is the central prop-
erty of the PGC-1 family.
Mitochondrial biogenesis is necessary to meet higher en-
ergy demands in a cell. This complex process requires tran-
scription of nuclear genes, import of the resulting proteins into
mitochondria, transcription of mitochondrial DNA, and its
replication. PGC-1 coactivators integrate these events in co-
operation with nuclear transcription factors 1 (NRF-1), NRF-2
(also called GA-binding protein or GABP), and ERRα that
induce nuclear-encoded mitochondrial genes like cytochrome
C oxidase subunit 4 (COX IV), β-ATP synthase, and mito-
chondrial transcription factor A (Tfam) [24, 29, 34, 35, 77]. In
turn, Tfam governs transcription and replication of mitochon-
drial DNA.
PGC-1α also induces NRF-1, NRF-2, and ERRα at the
expression level [25, 78]. Further signal amplification occurs
through NRF-2 and ERRα, which boost their own and each
others’ transcription respectively, to promote mitochondrial
biogenesis in biological switches [79].
Surprisingly, however, mice with a global deletion of either
PGC-1α or PGC-1β are viable, fertile, and do not show
overtly deranged mitochondria [80–83]. Their ability to cope
with different stress conditions (for example, exposure to
32 Semin Immunopathol (2014) 36:27–53
cold) is however grossly compromised. This indicates that
PGC-1 coactivators are less required for basal mitochondrial
function but are instrumental in orchestrating adaptations to
environmental challenges.
Interestingly, the PGC-1 coactivators affect mitochondrial
function in a specific manner. During electron transport, pro-
tons may leak over the inner mitochondrial membrane. Ec-
topic expression of PGC-1α in muscle cells promotes this
leakage to a larger extend than PGC-1β, although their effect
on respiration is comparable [84].
Mitochondrial biogenesis is accompanied by an increase in
ROS production. To alleviate the resulting oxidative stress,
PGC-1α and PGC-1β enhance the expression of ROS detox-
ifying enzymes like glutathione peroxidise 1 (GPx-1) and
mitochondrial superoxide dismutase [Mn], (Sod2). Accord-
ingly, PGC-1α acts neuroprotectively under oxidative stress
conditions [85].
Higher rates of oxidative phosphorylation require elevated
substrate supply. PGC-1α and PGC-1β augment fatty acid
oxidation by coactivating ERRα and PPARα in a constitutive
and a ligand-dependent manner, respectively, which propa-
gates the expression of key enzymes of this process such as
medium-chain specific acyl-CoA dehydrogenase (MCAD) [9,
17, 86]. In addition, PGC-1α fosters peroxisome biogenesis,
an organelle that catabolizes very long- and branched-chain
fatty acids [87]. In summary, PGC-1 coactivators drive a
whole program of oxidative metabolism to provide sufficient
amounts of energy to the cell.
In skeletal muscle, PGC-1α is abundant and particularly
enriched in slow twitch, oxidative muscle fibers that contain a
large number of mitochondria. Forced expression of PGC-1α
converts white muscles with mainly fast fibers into red mus-
cles with properties of slow-twitch type I and IIa fibers while
PGC-1β provokes a fiber type switch to type IIx fibers [88,
89]. In agreement with its role in oxidative myofiber determi-
nation, PGC-1α is transiently induced in skeletal muscle after
a single bout of endurance exercise and chronically elevated in
endurance trained muscle both in rodents and humans
[90–92].
Many, if not all, major adaptations of skeletal muscle in
response to endurance training are mediated by PGC-1α,
which therefore represents an important point of convergence
in the exercise-triggered signaling network. The formation of
a larger proportion of oxidative fibers requires mitochondrial
biogenesis, fatty acid uptake (e.g., by CD36), and oxidation
(e.g., by MCAD) in the myocyte to ensure adequate substrate
supply. All of these processes are coordinately regulated by
PGC-1α [93, 94]. PGC-1α also augments GLUT4 expression
in vitro and in vivo yielding higher glucose uptake intomuscle
cells [26, 94]. Pyruvate dehydrogenase kinase 4 (PDK4) is
induced concomitantly to promote fatty acid oxidation at the
expense of glucose metabolism [95]. Excess glucose that
cannot be diverted into glycolysis is consequently stored in
the form of glycogen and funneled into the pentose phosphate
pathway [94, 96, 97]. The resulting elevation of NADPH and
the PGC-1α-mediated activation of fatty acid synthase boost
de novo lipogenesis and thus increased storage of
intramyocellular lipids that serve as energy substrate. Thereby
PGC-1α coordinates anabolic and catabolic metabolic path-
ways in skeletal muscle [98].
Elevated ROS are a byproduct of higher mitochondrial
activity in contracting skeletal muscle. As ROS reinforce
PGC-1α expression, which contributes to ROS detoxification
by raising enzymes like Sod2 (see above), this negative feed-
back loop protects myocytes effectively from oxidative stress
[99, 100].
Apart from metabolic fluxes within the cell, PGC-1α also
tightly links muscle and nerve by regulating neuromuscular
junction genes and promoting acetylcholine receptors cluster-
ing at the motor end plate [101]. In addition, PGC-1α triggers
a remodeling of calcium handling in muscle cells towards a
slow fiber-type phenotype [102]. Finally, PGC-1α further
affects angiogenesis by potently inducing vascular endothelial
growth factor expression to maintain nutrient and oxygen
supply to muscles during sustained contractions [103, 104].
In combination, all of these PGC-1α-mediated changes
functionally translate into a higher endurance capacity as
observed in PGC-1α skeletal muscle-transgenic mice whereas
skeletal muscle-specific deletion of PGC-1α decreases perfor-
mance [96, 105].
The regulation and function of PGC-1β is much less clear.
For example, PGC-β is not uniformly influenced by exercise.
Nevertheless, when overexpressed in skeletal muscle, genes
involved in oxidative phosphorylation and fatty acid oxidation
are also upregulated by PGC-1β resulting structurally in a
higher mitochondrial density and functionally in a better en-
durance performance [89]. Inversely, skeletal muscle-specific
PGC-1β deletion causes lower endurance capacity [106]. A
combined deficiency of PGC-1α and PGC-1β in a global
PGC-1α and a muscle-specific PGC-1β knockout back-
ground aggravates this phenotype displaying a very severe
exercise deficit, strongly reduced oxidative capacity, and mi-
tochondrial structure and function derangements. However,
fiber type determination is only slightly changed in these mice
[106]. Similar to PGC-1α, PGC-1β was also shown to en-
hance angiogenesis [107]. It therefore appears that PGC-1α
and PGC-1β share some properties in skeletal muscle and can
potentially compensate for one another in some cases. The
role as “exercise factor” is however unique to PGC-1α, and
such a clear physiological function has not been assigned to
PGC-1β so far.
Aside from the regulation of endurance adaptations, PGC-
1α is a target of the myogenic regulatory factor MyoD in
terminal muscle differentiation and plays a role in regulating
circadian clocks in muscle [108, 109]. Interestingly, MyoD
itself is under the control of circadian transcription activators
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and their disruption perturbs muscle function as well as PGC-
1α and PGC-1β expression [110]. Further studies are needed
to investigate the mutual dependencies of PGC-1 coactivators,
MyoD, and clock genes to define their contribution to skeletal
muscle physiology.
Other organ-specific functions of PGC-1 coactivators
In addition to the regulation of oxidative metabolism, PGC-1
coactivators also execute an array of tissue-specific functions.
In the liver, PGC-1α is markedly upregulated in response to
fasting and controls several important starvation pathways
including gluconeogenesis and ketogenesis [18, 22, 49].
PGC-1α further governs hepatic heme, bile acid,
selenoprotein P, and homocystein biosynthesis [111–114].
PGC-1β by contrast is central to lipid metabolism in the liver
by inducing lipogenesis and the secretion of triglycerides/
VLDL into plasma [31, 33].
Cardiac PGC-1α is augmented both in development when,
perinatally, fatty acids replace glucose as main source of
energy, and in adult animals upon fasting. Lack of either
PGC-1α or PGC-1β promotes heart failure under stress con-
ditions while a PGC-1β cardiac deficiency combined with a
global PGC-1α gene ablation is lethal shortly after birth as
those hearts are unable tomature [115–118]. Inversely, cardiac
PGC-1α overexpression causes disturbances in the sarcomere
structure leading to dilated cardiomyopathy [119]. PGC-1
coactivator levels are thus only protective within a certain
window of expression.
PGC-1α was originally discovered as thermogenic regula-
tor in BAT induced by cold exposure [8]. BAT produces heat
by uncoupled respiration whereas white adipose tissue (WAT)
mainly stores energy in form of lipid droplets. Both PGC-1α
and PGC-1β are critical for adequate BAT function and par-
ticipate in brown fat lineage determination [118, 120, 121].
Induction of PGC-1α inWAT thus results in “browning”while
PGC-1α suppression favors a white adipocyte phenotype
[122–125]. Accordingly, mice with an adipose tissue-specific
deletion of PGC-1α on high fat diet develop insulin resistance
as the excess energy cannot be sufficiently dissipated [126].
In pancreas, both PGC-1α and PGC-1β are involved in
glucose-stimulated insulin secretion from β cells; their contri-
bution is however controversial as suppression and induction
of insulin release have been reported [32, 127, 128].
Both coactivators control mitochondrial density in nerve
cells [129]. Neuroprotection through PGC-1α was shown in
the contexts of oxidative stress and amyotrophic lateral scle-
rosis whereas neurodegeneration is associated with a loss of
PGC-1α in various disorders including Huntington’s and
Alzheimer’s disease [85, 130–132]. Consistently, global and
brain-specific deletion models of PGC-1α exhibit striatal de-
generative lesions and increased susceptibility for other neu-
rodegenerative events [80, 133].
PGC-1α also plays a role in light damage-induced retinal
regeneration and function and in chondrogenesis [134, 135].
PGC-1β is further implicated in osteoclast activation and PRC
has a non-redundant function in proliferative growth [136, 137].
PGC-1 coactivators in skeletal muscle pathology
Skeletal muscle exhibits considerable plasticity and adapts to
different training regiments as well as disuse. While endur-
ance exercise induces PGC-1α as described above, different
experimental or pathological muscle wasting conditions like
denervation-induced atrophy, statin treatment, diabetes, ure-
mia, and cancer cachexia reduce PGC-1α and/or PGC-1β
levels [138–141]. Accordingly, ectopic expression of PGC-
1α or PGC-1β counteracts the atrophic state by suppressing
atrogenes in vitro and in vivo [140–142]. PGC-1 coactivators
are thus able to preserve muscle structure and function under
unfavorable circumstances. This observation extends to
sarcopenia (progressive muscle loss with age) as old mice
with transgenic PGC-1α expression in skeletal muscle show
a higher degree of muscle integrity, improved mitochondrial
function, and better exercise performance than age-matched
wild-type animals [100].
Several inherited disorders affect skeletal muscle function.
Duchenne muscular dystrophy (DMD) is caused by a muta-
tion in dystrophin. Mutated dystrophin fails to link the cyto-
skeleton to the extracellular matrix leading to muscle degen-
eration and premature death. Mitochondrial myopathies stem
from mutations in mitochondrial DNA. Skeletal muscle-
specific overexpression of PGC-1α is able to antagonize
symptoms of both disorders in respective mouse models
[101, 143]. PGC-1α therefore dampens fiber damage and
preserves muscle function in those contexts. A non-genetic
approach deploying endurance training also raised PGC-1α
levels and protected mice with mitochondrial myopathy [144].
The etiology of Huntington’s disease (HD) involves loss of
muscle mass which coincides with a reduction of PGC-1α
expression in rodents and humans. This wasting phenotype
could be improved by artificially increasing PGC-1α levels in
skeletal muscle [145].
Genetic and acquired obesity are strongly correlated with
the development of insulin resistance and diminish both PGC-
1α and PGC-1β levels in rodent skeletal muscle [146]. In
human diabetic patients, a coordinate suppression of genes
involved in oxidative phosphorylation has been observed con-
comitant with a reduction of PGC-1α and PGC-1β in some,
but not all studies [147–149]. This suggests that dysregulated
PGC-1 coactivator levels may account for disturbed energy
metabolism in skeletal muscle contributing to the development
of insulin resistance. Inversely, a moderate PGC-1α increase in
skeletal muscle improves insulin sensitivity through the selec-
tive elevation of fatty acid oxidation in subsarcolemmal, but
not intermyofibrillar mitochondria [150].
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The relationship between PGC-1 coactivators and insulin
resistance is however more complex as two independent
mouse strains lacking PGC-1α are less susceptible to diet-
induced obesity possibly owing to hyperactivity, which is
likely a consequence of striatal brain lesions [80, 81]. Skeletal
muscle-specific deletion models still display higher peripheral
insulin sensitivity; however, they do become glucose-
intolerant on a high fat diet. This puzzling phenotype is the
result of muscle-islet crosstalk whereby muscle-derived IL-6
and possibly other factors might impair insulin secretion
from pancreas leading to a deficit in glucose clearance
from blood but at the same time to high insulin sensi-
tivity in the periphery [151].
Surprisingly, muscle-specific PGC-1α overexpressing ani-
mals develop insulin resistance at an accelerated pace on high
fat diet compared with wild-type mice presumably due to
excess lipid storage within muscle cells [152]. Interestingly,
the same model is however protected from sarcopenia and
preserves insulin signaling and sensitivity until old age [100].
In a twin study, PGC-1α and PGC-1β emerged as factors
declining with age which might contribute to an increased risk
of diabetes in this phase of life [153]. Dropping PGC-1α
levels are associated with the common Gly482Ser variant,
but an unequivocal mechanistic link of this polymorphism to
diabetes could not be established as the serine containing
variant seems fully functional [154–156]. A polymorphism
within the PGC-1α promoter however clearly contributes to
diabetes in Koreans and Austrians [157, 158].
PGC-1β protects mice from genetic and acquired obesity,
but without effect on whole-body glucose metabolism or
skeletal muscle insulin sensitivity [29, 82, 159]. Loss of
function however promotes hepatic insulin resistance because
of lipid accumulation in the liver [82, 159]. Yet, genetic
linkage studies failed to prove a clear association of the
Ala203Pro variant with obesity or diabetes [160, 161].
A PGC-1α/PGC-1β double-deficient model based on
global PGC-1α and muscle-specific PGC-1β gene ablation
surprisingly is unaffected in terms of glucose or insulin toler-
ance on different diets. Importantly, however, the global PGC-
1α deletion background confounds interpretation of these
findings due to its complex brain phenotype [106].
Pharmacological treatment of mice with resveratrol pro-
tects them from diet-induced obesity and insulin resistance as
Sirt1-dependent PGC-1α activation stimulates oxidative me-
tabolism in skeletal muscle [162, 163]. Furthermore, the
insulin-sensitizing properties of thiazolidinediones are at least
partially ascribed to an induction of PGC-1α and the concom-
itant restoration of mitochondrial bioenergetics in muscle,
e.g., in db/db mice [164].
Targeting PGC-1 coactivators in skeletal muscle to fight
musculoskeletal and metabolic diseases and especially in-
crease insulin sensitivity is therefore a worthwhile venture.
There is however a therapeutic window for these beneficial
effects as excessive PGC-1 coactivator levels may act coun-
terproductive [165]. Dysregulation of these coactivators in
other organs further complicate treatment as, for example, in
liver and pancreas of diabetic patients, PGC-1α levels are
increased which contributes to pathology in these tissues
[165]. Finding potent and specific PGC-1α and PGC-1β
activators and inhibitors is thus of prime interest.
Inflammation
Major molecular pathways in inflammation
Inflammation is the protective response of the body to harmful
insults like pathogens and wounding aiming at defense and
repair to secure the organism’s integrity. The immune system
has evolved to govern these inflammatory reactions and com-
prises two branches, innate and adaptive immunity, respec-
tively. The innate immune system is able to react rapidly and
initiate an inflammatory reaction within minutes. The adaptive
immune system operates secondarily and thus delayed, but is
highly specific. Immune cells communicate with injured or
infected cells and other immune cells via small, soluble pep-
tides, so-called cytokines, which may elicit, potentiate, or
dampen inflammation and thus fundamentally influence its
progression. Potent pro-inflammatory cytokines include the
tumor necrosis factorα (TNFα), interleukin 1β (IL-1β), IL-6,
and macrophage inflammatory protein 1α (MIP-1α) while IL-
4, IL-10, IL-13, and IL-1 receptor antagonist (IL-1Ra) act
primarily as anti-inflammatory cytokines [166].
To transmit their signals, cytokines bind to cytokine recep-
tors. These are grouped into different families according to
their structure. Type I and type II cytokine receptors are
multimeric transmembrane receptors that signal via the janus
kinase (JAK)–signal transducers and activators of transcrip-
tion (STAT) pathway while chemokine receptors are G
protein-coupled receptors (GPCRs) with seven transmem-
brane domains that signal through G proteins. Members of
the TNF receptor (TNFR) family oligomerize upon ligand
binding. They are associated with adaptor proteins that may
activate inflammatory or apoptotic pathways via TNFR-
associated factors (TRAFs) and the caspase cascade, respec-
tively. The transforming growth factor β (TGFβ) receptor
family has three members that connect to SMAD proteins.
Finally, some cytokine receptors belong to the immunoglob-
ulin (Ig) superfamily.
Pathogens contain conserved structures, so-called
pathogen-associated molecular patterns (PAMPs) that can be
recognized by the host’s immune system to initiate inflamma-
tion. PAMPs bind to Toll-like receptors (TLRs), which are
expressed on the surface of immune and most other cells. So
far, 12 mammalian TLRs with different binding specificities
have been identified, e.g., TLR4 detecting lipopolysaccharide
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(LPS). TLRs signal through adaptor proteins like myeloid
differentiation primary response gene 88 (Myd88) that further
activate IL-1R-asscoiated kinases (IRAKs) and TRAFs finally
leading to inflammation [167].
While STATs and SMAD proteins are able to translocate to
the nucleus and modulate transcription of inflammatory genes
directly, GPCR signaling typically leads to the production of
second messengers. TRAF activation downstream of TNFRs
and TLRs causes activation of the NF-κB pathway [167]. This
pathway is central to inflammatory reactions and has been
shown to be involved in a large number of diseases. NF-κB
activating signals converge at the inhibitor of κB (IκB) kinase
(IKK) complex which comprises three subunits, IKKα, IKKβ
(both catalytic), and IKKγ/NF-κB essential modulator
(NEMO, regulatory). Canonical NF-κB signaling involves
activation of IKK, which subsequently phosphorylates IκB
preexisting in a cytosolic complex with NF-κB.
Phosphorylation-induced polyubiquitination targets IκB for
proteasomal degradation, consequently releasing NF-κB that
then translocates to the nucleus where it binds to κB sites and
thus promotes transcription of inflammatory genes [168].
NF-κB binds DNA as homo- or heterodimer, and five
different NF-κB familymembers are known: RelA/p65, RelB,
c-Rel, p100/p52, and p105/p50 that all share an N-terminal
Rel homology domain (RHD). P65, RelB, and c-Rel addition-
ally contain a transactivation domain (TAD) which facilitates
transcription whereas p50 and p52 homodimers act repressive
as they lack this domain. The most common and best studied
NF-κB dimer is p65/p50 [168].
Several ankyrin repeat domains are characteristic for the
IκB family. The typical members IκBα, IκBβ, and IκBε
sequester NF-κB dimers in the cytosol. They are degraded at
different rates upon stimulation and also possess specific re-
synthesis kinetics [169]. As NF-κB target genes, the IκBs
initiate a negative feedback loop to terminate NF-κB signaling
[170]. The atypical IκB family members IκBγ, B cell lym-
phoma 3 (Bcl3), and IκBζ bind to NF-κB dimers in the
nucleus and modulate their transcription activation potential
at this level [168]. The precursor proteins p100 and p105 can
also be classified as IκBs with ankyrin repeat domains despite
constitutive processing to p52 and p50 even in the basal state.
P100 and p105 may also dimerize with other NF-κB subunits,
e.g., RelB and c-Rel, respectively, retaining this complex in
the cytosol in unstimulated cells. Stimulus-dependent process-
ing of p100 and p105 to p52 and p50 then yields active NF-κB
dimers [168].
The canonical pathway described above involves the
heterotrimeric IKK complex, IKKβ-dependent phosphoryla-
tion of IκBα, and subsequent release of p65/p50 [168, 171].
While IKKα is dispensable for canonical signaling, it is
required for noncanonical NF-κB activation [172]. The non-
canonical pathway is initiated by IKKα dimers that phosphor-
ylate p100 upon stimulation. As p100 preexists in a complex
with RelB, processing to p52 generates the RelB/p52 dimer,
which is able to induce a subset of NF-κB target genes [173].
Noncanonical NF-κB activation has been described, for ex-
ample, downstream of CD40, lymphotoxin β receptor
(LTβR), and B cell activating factor receptor (BAFFR)
[174–176].
PTMs of NF-κB subunits also influence inflammatory sig-
nals, and p65 has been studied extensively in this regard.
Inducible phosphorylation, acetylation, ubiquitylation, prolyl
isomerisation, poly(ADP-ribosyl)ation, monomethylation, and
S-nitrosylation have been reported so far. Their presence affects
the subcellular localization, the stability of DNA binding, and
the affinity to coactivator and corepressor complexes which
determine the NF-κB transcription activation potential [168].
Besides the NF-κB pathway, activator protein 1 (AP-1)
signaling plays an important role in inflammatory reactions.
The induction of MAPK cascades, e.g., downstream of TNFR
and TLRs, leads to activation of AP-1, which, similar to
NF-κB, is a homo- or heterodimeric transcription factor. The
subunits belong to the Jun, Fos, or activating transcription
factor (ATF) families of basic-region leucine-zipper (B-ZIP)
proteins that bind DNA at specific sequences and thus induce
transcription of inflammatory target genes. A well-studied
example is the activation of JNK, which in turn translocates
to the nucleus where it phosphorylates c-jun, thereby promot-
ing AP-1’s transcription activation potential [177, 178].
Finally, interferon regulatory factors (IRFs) mediate the
induction of interferons and are as such critical in the response
to viral infections [179].
The many players within the NF-κB and AP-1 pathway
illustrate the complexity and redundancy of inflammatory
signaling. This complexity is necessary to allow the body to
mount a highly specific immune response to different kinds of
injury and infection in order to protect the body at all times.
The nature of inflammation is transient, and therefore termi-
nation of immune responses is as important as initiation. If
inflammatory reactions do not resolve and become chronic,
they in fact turn detrimental and harmful to the body. Chronic
inflammation also accompanies many pathologies including
type 2 diabetes and cardiovascular diseases.
Inhibition of inflammation may occur at several levels.
Changes in gene expression of the pro-inflammatory tran-
scription factors themselves and/or their upstream regulators
affect inflammatory promoters. Examples are the resynthesis
of IκB proteins that retain NF-κB in the cytosol and thus block
transcription, and the induction of repressive p50 or p52
homodimers that compete for κB sites in the nucleus [168].
PTMs also interfere with inflammatory signaling. Suppres-
sor of cytokine signaling 1 (SOCS1), for example, is able to
ubiquitinate p65, and its overexpression inhibits IL-1β-
dependent NF-κB activation [180]. Then, A20-deficient mice
develop severe inflammation because the dual ubiquitin-
editing enzyme A20 targets important signaling molecules
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like RIP1 and TRAF6 for degradation, thereby confining
inflammatory processes [181, 182]. As phosphorylation
events are important during the activation of most inflamma-
tory pathways, changes in kinase and phosphatase activity
influence pro-inflammatory gene expression. Again, the
NF-κB pathway provides excellent examples: IKKβ-
deficientMEFs can neither phosphorylate IκBα nor p65 while
IKKα-deficient MEFs normally degrade IκBα but are still
unable to phosphorylate p65, which blunts transcription from
NF-κB-inducible promoters [183]. Inversely, mice lacking
Wip1, the only known p65-specific serine phosphatase, dis-
play increased NF-κB target gene expression alongside higher
p65 phosphorylation levels [184].
Transrepression by NRs has emerged as a potent mecha-
nism to confine inflammation. Accordingly, PPARα activa-
tion reduces expression of IL-6, cyclooxygenase 2 (COX2),
vascular cell adhesion molecule 1 (VCAM1), and other in-
flammatory factors in different cell types whereas PPARα
deletion renders mice hypersensitive to LPS [185–187].
PPARγ ligands and glucocorticoids, activators of the GR,
likewise exhibit strong anti-inflammatory effects [188–191].
In contrast to transactivation that requires direct NR-DNA
binding, transrepression may occur indirectly without direct
contact to DNA.
Several molecular mechanisms of transrepression were
established so far. DNA–binding-dependent or DNA–bind-
ing-independent induction of IκBα as shown for PPARα
terminates NF-κB target gene expression [192–194]. More-
over, competition for a limiting pool of coactivators like CBP
results in mutual antagonism between inflammatory and NR
pathways [195, 196]. NRs may also disrupt the coactivator
complex at inflammatory transcription factors by binding ei-
ther to the transcription factor, thus preventing coactivator
binding (e.g., GR on p65) or to the coactivator thus hindering
its recruitment [197]. Additional cofactors like nuclear TR-
interacting protein 6 may favor GR binding, which in turn
promotes transrepression, while secondary recruitment of co-
repressors like glutamate receptor-interacting protein or
CoREST propagate this state [198–200]. PPARγ and LXR
can further inhibit corepressor clearance from NF-κB by
preventing proteasomal degradation of NcoR1 in a ligand-
and SUMOylation-dependent manner [201, 202].
SUMOylation is also implicated in LXR-mediated
transrepression of STAT1 downstream of interferon signaling
[203]. Furthermore, PPARα interacts with both c-jun and p65
to repress AP-1- and NF-κB-driven gene expression, respec-
tively [204]. As a consequence of this direct interaction, NR
and inflammatory signaling pathways reciprocally interfere
with each other constituting a negative cross-talk. Finally,
GR may also constrain both transcription initiation and elon-
gation by blocking RNA polymerase II hyperphosphorylation
and chromatin remodeling by tethering HDACs to promoters
of inflammatory genes [205–208].
Obesity and inflammation
Overweight and obesity do not only increase the risk for
metabolic complications like insulin resistance but also foster
a sterile, low-grade inflammation. This is evidenced by high
plasma levels of circulating pro-inflammatory cytokines (IL-
1, IL-6, IL-8, IL-12, and TNFα), chemokines (monocyte
chemoattractant protein (MCP) 1/CCL2, RANTES/CCL5,
MIP-1), acute phase proteins (C-reactive protein, serum
amyloid A, ferritin), adipokines associated with insulin resis-
tance (retinol binding protein 4 and resistin), and
procoagulative and hypertensive factors (plasminogen activa-
tor inhibitor 1 and angiotensinogen) in obese patients [209].
Inversely, negative acute phase proteins (transcortin and trans-
ferrin) and adipokines associated with insulin sensitivity
(adiponectin, visfatin, omentin, and vaspin) are lowered in
plasma of those subjects [209].
As expansion of adipose depots is the prime effect of
obesity, an inflammatory reaction in WAT is the major source
of elevated circulating pro-inflammatory factors [210]. WAT
inflammation thereby involves both adipocytes and different
immune cells that reside within WAT. Activation of the
NF-κB and AP-1 pathways in adipocytes is a critical event
in this process as it leads to expression and secretion of pro-
inflammatory cytokines but also to adipocyte insulin resis-
tance because IKK and JNK are able to phosphorylate IRS1 at
inhibitory serine residues [211]. Consequently, JNK deletion
ameliorates insulin resistance and improves insulin receptor
signaling in obese animals [212].
To date, it is unknown which primary stimulus sets off the
inflammatory reaction, but a number of aberrantly active
cellular processes in WAT of obese subjects were shown to
contribute. The presence of pro-inflammatory cytokines pro-
motes IKK and JNK activation and indeed treatment of adi-
pocytes with TNFα inhibits IRS1 action. In contrast, animals
with disrupted TNFα signaling are protected from obesity-
induced insulin resistance [211, 213]. High levels of free fatty
acids that prevail in obesity are able to induce pro-
inflammatory TLR signaling, and consequently, TLR4 dele-
tion rescues animals from obesity-induced insulin-resistance
[214]. Furthermore, ROS levels are aberrantly high in accu-
mulated fat, producing oxidative stress and, as a result,
NF-κB/AP-1 signaling [215]. If the capacity of adipocytes to
store fat is exceeded, ER stress arises and free fatty acids leak
into the cytoplasm where they in turn activate JNK [216]. The
expansion of adipocytes might also outbalance angiogenesis,
which leads to tissue hypoxia and the induction of hypoxia-
inducible factor 1α (HIF-1α) that itself promotes pro-
inflammatory cytokine expression [217]. In combination, ER
stress and hypoxia exacerbate adipocyte necrosis. The dying
cells then nucleate the formation of crown-like structures
(areas of necrotic cells surrounded by macrophages), which
are absent in lean animals [218].
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Adipose tissue macrophages (ATMs) are plastic cells that
may polarize towards an anti-inflammatory M2 or a pro-
inflammatory M1 state. The two phenotypes are characterized
by the distinct sets of cytokines that they express. Hence, the
highly inflammatory TNFα, IL-1β, and IL-6 are secreted by
M1 macrophages while M2 macrophages produce anti-
inflammatory factors like IL-10. In WAT of lean animals,
M2 macrophages are more prominent than M1 macrophages.
Their polarization is driven by adipocyte-derived IL-13, IL-4,
and adiponectin as well as the prevalence of unsaturated free
fatty acids leading to PPAR activation [219–221]. Ac-
cordingly, myeloid ablation of PPARγ or PPARβ/δ im-
pairs M2 skewing and fosters inflammation and insulin
resistance [219, 222]. M2 macrophages exhibit an oxi-
dative metabolic profile, and PGC-1β is essential in
initiating M2 polarization [223].
In contrast, M1 macrophages are highly enriched in WAT
of obese animals where they amplify and sustain tissue in-
flammation [224, 225]. The altered cytokine/adipokine profile
in fat, high levels of saturated free fatty acids, and the emer-
gence of crown-like structures promote the phenotypic switch
from M2 to M1 macrophages [226]. M1 macrophages also
express MCP-1, which attracts monocytes that migrate from
the circulation into WAT where they differentiate into M1
macrophages further perpetuating inflammation. Adipose
tissue-specific overexpressing of MCP-1 thus renders animals
insulin-resistant, while deletion of the MCP-1 receptor CCR2
prevents M1 macrophage accumulation and maintains insulin
sensitivity under high fat feeding [227–229]. Similarly, mye-
loid deletion of TLR4, JNK, or IKKβ interferes with M1
macrophage polarization and consequently rescues insulin
sensitivity on a high fat diet without differences in body
weight gain [230–232].
Besides ATMs, other immune cells contribute to both anti-
inflammatory, insulin-sensitive and the pro-inflammatory,
insulin-resistant states. Eosinophils, CD4+ regulatory T, and
Th2 cells all reside in WAT of lean animals where they
preserve M2 macrophage activation and insulin sensitivity
while the T cell balance in obese animals tips towards Th1
cells that secret IFNγ, hence skewing macrophages towards
the M1 phenotype [233–236]. This polarization is further
advanced by pro-inflammatory neutrophils, CD8+ effector T
cells, and B cells that all have been detected in WAT in the
early stages of obesity [237–239]. Therefore, depletion of
immune cells types associated with M1 polarization or induc-
tion of M2-sustaining immune cells ameliorates insulin resis-
tance [233, 234, 239, 240].
In other organs, inflammatory reactions during the course
of obesity have received less attention. The liver plays a major
role in glucose metabolism due to hepatic gluconeogenesis.
M1 polarization of Kuppfer cells (liver macrophages) is now
thought to contribute to hepatic inflammation, insulin resis-
tance, and steatosis. Recently, pancreaticβ cell failure has also
been linked to islet inflammation and M1 macrophage accu-
mulation [241]. It therefore appears that inflammation with
M1 macrophage polarization could be a general mechanism
underlying organ dysfunction in obesity.
The situation in skeletal muscle is somewhat less clear.
Intramuscular fat depots form in obese animals and attract
inflammatorymacrophages, however to a much smaller extent
compared to bona fide adipose tissue [224]. These macro-
phages exert a negative influence on muscle insulin sensitivity
as shown in obese animals with myeloid deletion of either
JNK or IKKβ [231, 232]. In these models, inhibition of M1
macrophage activation preserved muscle insulin sensitivity
[231, 232]. The same effect was observed after depletion of
Cd11c+ cells that correspond to the main M1 macrophage
subset in muscle [242]. Inversely, even lean animals with
myeloid deletion of PPARγ developed muscle insulin resis-
tance, which deteriorated in the obese state due to impaired
M2 macrophage polarization [243]. In contrast, myeloid de-
letion of PPARβ/δ or TLR4 did not entail any effect on
muscle insulin sensitivity [219, 230].
These observations imply that skeletal muscle insulin re-
sistance is at least partially regulated by mechanisms that are
different from WAT. Investigating these common and distinct
processes in skeletal muscle warrants further studies. The
caveat of myeloid deletion approaches is however that all
macrophages in the body are polarized towards one or the
other phenotype. Distinguishing between purely skeletal
muscle-specific cross-talk of macrophages and myocytes ver-
sus whole body effects on the muscle, e.g., through generally
lower circulating cytokine levels, remains a difficult endeavor.
Future experiments will have to discern the exact role of M1
and M2 macrophages in skeletal muscle under conditions of
obesity.
Inflammatory pathways in skeletal muscle
Adult skeletal muscle contains substantial amounts of differ-
ent NF-κB family members; their role in muscle physiology is
however not fully resolved. It is unclear whether NF-κB is a
pro-myogenic or an anti-myogenic factor during muscle dif-
ferentiation as relevant data are conflicting, but suppression of
myogenesis by means of inhibiting MyoD, myogenin, and
myofibrillar gene expression has been linked to canonical
NF-κB signaling [244–252]. In contrast, noncanonical
NF-κB signaling that involves IKKα and RelB does not affect
myogenesis but drives an oxidative muscle fiber switch by
targeting PGC-1β, which stimulates mitochondrial biogenesis
[253]. Exercise-dependent NF-κB activation has also been
reported in skeletal muscle and potentially induces ROS de-
fense, regeneration of damaged fibers, and adaptations in fuel
metabolism [254–256].
In muscle pathology, inflammatory reactions accompany a
number of disorders like cachexia, muscular dystrophy,
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atrophy, and inflammatory myopathies [257]. NF-κB activa-
tion in these contexts is a well-established disease mechanism
that contributes significantly to deterioration of muscle func-
tion. This also is evident in mice with skeletal muscle-specific
overexpression of IKKβ, which causes severe muscle wasting
while muscle-specific deletion of this kinase improves
strength and counteracts denervation-induced atrophy and
fiber type changes [258, 259]. Moreover, the latter model,
similar to a p65 deletion model, regenerates faster from injury
as inflammation is substantially inhibited in both mouse lines
[252, 259].
Regeneration of skeletal muscle requires the activation of
satellite cells (muscle stem cells), their fusion to damaged
fibers, or the formation of new fibers depending on the degree
of injury. Satellite cell proliferation is stimulated by IL-6 while
IL-4 promotes myoblast fusion [260, 261]. Satellite cells also
attract and interact with monocytes/macrophages to foster
muscle growth [262]. Therefore, macrophages are also en-
gaged in the different stages of regeneration:M1macrophages
(CD68+/CD163−) readily remove cellular debris by phago-
cytosis directly after injury and contribute to satellite cell
activation while M2 macrophages (CD68−/CD163+) invade
the tissue later [263]. They promote satellite cell differentia-
tion and muscle growth in later regenerative stages to restore
muscle function [264]. The M1/M2 macrophage switch is
presumably initiated by muscle-derived IL-4 [261]. In
dystrophic muscle, M1 macrophage activation and con-
comitant M2 macrophage repression, e.g., by IFNγ ex-
acerbates muscle wasting in DMD while, conversely,
symptoms are alleviated by IL-10, which activates M2
and represses M1 macrophages [265, 266].
PGC-1 coactivators and inflammation in skeletal muscle
Anti-inflammatory effect of exercise
Skeletal muscle has been recognized as an endocrine organ
that releases myokines (muscle-derived cytokines) like IL-6,
IL-8, and IL-15 during contraction [267]. These myokines
presumably mediate beneficial effects of exercise both on
the muscle itself and on distant organs. IL-6 has received most
of the attention and the majority of studies deal with this
myokine. The induction of IL-6 after exercise was speculated
to be under the control of nuclear factor of activated T cells
(NFAT) and/or p38/MAPK as opposed to NF-κB during
inflammatory reactions [268]. While elevated IL-6 levels are
also associated with chronic inflammation, the contraction-
induced rise of IL-6 is transient and thus not detrimental.
Accordingly, IL-6 infusion increases insulin-stimulated glu-
cose disposal in humans whereas deletion of IL-6 in mice
results in mature-onset diabetes [269, 270]. Importantly, IL-6
receptor expression is augmented concomitantly to IL-6 post
exercise. This heightens “IL-6 sensitivity” while reciprocally,
under conditions of chronic inflammation, “IL-6 sensitivity”
might be lost (analogous to insulin resistance with high levels
of insulin) [271].
Diseases that are associated with a systemic, low-grade
inflammation may be antagonized by physical activity, e.g.,
diabetes, sarcopenia, and neurodegeneration [272–275].
Muscle-derived IL-6 preludes expression of the anti-
inflammatory cytokines IL-1Ra and IL-10 in blood while
inhibiting pro-inflammatory TNFα production [276, 277].
This skews the immune reaction towards a type 2 response.
Following contraction, plasma levels of immunomodulato-
ry hormones like epinephrine, cortisol, growth hormone, and
prolactin are all high and suppress inflammatory reactions
[272]. On monocytes, exercises reduce TLR1, TLR2, and
TLR4 expression and function, alongside a decrease in major
histocompatibility complex II and costimulatory mole-
cules rendering these cells less inflammatory [278].
Potentiation of these effects after very strenuous training
leads to temporary immunodepression as observed in
high-performance athletes [272].
Mutual influence of inflammatory factors and PGC-1s
Inflammatory stimuli affect endogenous PGC-1 coactivator
levels in different organs whereby LPS-induced sepsis is the
most extensively studiedmodel in this regard. In heart, kidney,
and liver, PGC-1α, ERRα, and MCADmRNAwas markedly
reduced 16 h after LPS injection [279]. Furthermore, in car-
diac tissue, inflammation-dependent PGC-1α repression was
further confirmed in vitro and in vivo, which could be rescued
by inhibiting the NF-κB pathway [280–282]. Sepsis-
associated acute kidney injury is associated with swollen,
dysfunctional mitochondria and reduced PGC-1α levels that
correlate with renal impairment [283]. This phenotype can be
recapitulated by treatment of tubular cells with TNFα and
reversed by excess PGC-1α while lack of this coactivator
results in persistent kidney injury after endotoxemia [283].
In contrast, one study reported an opposite regulation of PGC-
1α and PGC-1β in liver of septic mice, as both coactivators
were induced in a TLR2-dependent manner [284].
In skeletal muscle, the regulation of PGC-1 coactivators by
inflammatory stimuli is ambiguous. An early study found that
LPS, TNFα, and IL-1β augment PGC-1α expression,
resulting in increased oxidative phosphorylation while, more
recently, sepsis was shown to lower PGC-1α and PGC-1β in
skeletal muscle of rats [61, 285]. In support of these data,
PGC-1α and PGC-1β are also reduced in diaphragm after
LPS administration with concomitant decrease in fatty acid
oxidation [286]. A more careful examination of the time-
course revealed that intraperitoneal injection of LPS induced
PGC-1α in skeletal muscle after 2 h, but decreased its expres-
sion after 24 h, suggesting a short-term upregulation but a
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long-term downregulation [287]. This model is also well in
line with the induction of PGC-1α after exercise in the tran-
sient presence of myokines that return to basal levels quickly
as opposed to the chronic, low-grade inflammation observed
in metabolic disorders with dampened PGC-1 coactivator
levels in skeletal muscle. A repression of PGC-1α and PGC-
1β upon chronic TNFα or IL-1β exposure was also observed
in C2C12 myotubes [288]. Importantly, inflammatory stimu-
lation with the activation of classical NF-κB signaling clearly
impaired the oxidative phenotype in this system [288]. Cell
cul ture studies with palmita te fur ther back the
abovementioned, dual regulation as long-term treatment re-
pressed, while short-term treatment increased PGC-1α ex-
pression [289]. However, one study also associated long-
term palmitate administration with an increase in PGC-1α in
vascular smooth muscle cells [290].
A pathological condition frequently associated withmuscle
wasting and low oxidative capacity is chronic obstructive
pulmonary disease (COPD). COPD patients also exhibit high
TNFα levels in skeletal muscle alongside decreased PGC-1α
expression [291]. This repression can be replicated in vitro by
chronically treating the C2C12 muscle cell line with TNFα.
The subsequent inhibition of oxidative phosphorylation is
dependent onNF-κB [291, 292]. Similarly, TNFα is augment-
ed in mice exposed to cigarette smoke while PGC-1α levels in
skeletal muscle of these animals are diminished [292]. The
impairment in expression of PGC-1α and some of its target
genes is more pronounced in oxidative muscles [292]. Of
note, plasma TNFα levels in COPD patients negatively cor-
relate with PPARα expression in skeletal muscle [293]. Over-
all, these data imply that chronic inflammatory stimulation
and especially NF-κB signaling lead to a suppression of PGC-
1 coactivator levels.
An inverse, body mass index-independent correlation be-
tween PGC-1α and IL-6 as well as TNFα expression is also
present in skeletal muscle of diabetic patients [151]. In accor-
dance, mouse models that lack PGC-1α in skeletal muscle or
only express it heterozygously display higher IL-6 levels in
muscle and blood [151]. Complete lack of muscle PGC-1α
further promotes the expression of pro-inflammatory markers
like TNFα and CD68 in skeletal muscle [151]. After exercise
that increases PGC-1α levels in wild-type mice, excessive
TNFα expression in muscle and blood can be observed in
this model [105]. Therefore, low PGC-1α levels in skeletal
muscle are associated with inflammatory processes in muscle
and the appearance of circulating pro-inflammatory cytokines.
A causal relationship between PGC-1 coactivators and
inflammation has recently been established. PGC-1α and
PGC-1β were shown to diminish the increase in pro-
inflammatory cytokine expression elicited by TNFα, TLR
agonists, and saturated free fatty acids in C2C12 muscle cells
[294]. In human aortic smooth muscle and endothelial cells,
PGC-1α likewise decreased TNFα-induced VCAM-1 and
MCP-1 expression [295]. Mechanistically, the PGC-1
coactivators target the NF-κB pathway and for example
dampen expression of luciferase from an NF-κB-drive report-
er in vitro and in vivo [142, 294]. More precisely, the PGC-1s
lower phosphorylation of p65 in C2C12 cells and muscle-
specific PGC-1α transgenic mice [100, 294]. One study how-
ever found elevated p65 phosphorylation levels in this model
and no difference between wild-type and transgenic mice
concerning muscle IL-6 and TNFα expression after short-
term, intraperitoneal LPS injection [296]. In vitro,
transrepression by PPARα is a second mechanism that con-
tributes to the repression of pro-inflammatory cytokines in
skeletal muscle cells [294].
Together, these results suggest that PGC-1 coactivators and
inflammatory processes in skeletal muscle are linked in a
reciprocal manner (Fig. 2). Therefore, high PGC-1 expression
not only determines an oxidative metabolic state but also
favors an anti-inflammatory environment (Fig. 2a). Inversely,
pro-inflammatory cytokines suppress PGC-1 coactivators
leading to a more glycolytic metabolism in a highly inflam-
matory environment (Fig. 2b). The NF-κB pathways appears
to be a nodal point in this mutual repressive action as NF-κB
signaling strongly induces pro-inflammatory genes and at the
same time suppresses PGC-1 coactivator expression. Con-
versely, at least canonical NF-κB signaling can be restrained
by PGC-1 coactivators constituting an interdependent, nega-
tive, molecular regulation of oxidative metabolism and in-
flammation in muscle cells (Fig. 2).
In macrophages, this antagonism has previously been de-
scribed during alternative activation which is associated with a
decrease in the expression of pro-inflammatory markers and
requires PGC-1β induction [223]. These M2 macrophages
show signs of an oxidative metabolic program as opposed to
M1 macrophages that rely mainly on glycolysis as energy-
producing pathway. PGC-1β expression in macrophages fur-
thermore drives the generation of mitochondrial ROS, which
are vital in pathogen clearance [297]. The role of PGC-1α in
macrophages is not well understood, but it likely participates
in M2-like polarization as hypothesized for macrophages in
epidydimal adipose tissue while it is downregulated after LPS
exposure which leads to M1 macrophage polarization [298,
299]. PGC-1α inhibition in this case enables ROS production
as many ROS-detoxifying enzymes are among PGC-1α target
genes [299].
M1 and M2 macrophage-polarizing signals are mutually
exclusive and thus preclude the opposite activation state. The
anti-inflammatory cytokines IL-4, IL-10, and Il-13, for exam-
ple, suppress M1 macrophage activation because they disturb
NF-κB signaling and STAT1 activation by inducing inhibitory
p50 dimers and STAT3/STAT6 [300, 301]. STAT6 is an im-
portant molecular determinant of M2 macrophage activation
that cooperates with Krüppel-like factor 4 (KLF4) to induce
anti-inflammatory M2 and inhibit pro-inflammatory M1
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genes [302]. Similarly, KLF2 also impairs NF-κB activation
[303]. PPARγ and PPARβ/δ are required for M2 macrophage
polarization. They induce both a more oxidative metabolic
program within these immune cells and simultaneously
transrepress pro-inflammatory promoters, which renders these
nuclear receptors central players in the dichotomy between
M1 and M2 macrophages reflecting the antagonism between
oxidative metabolism and inflammatory gene expression
[219, 222, 304]. If this adverse regulation that we propose to
take place in macrophages andmuscle cells also plays a role in
other tissues remains to be determined. For example, canon-
ical NF-κB signaling has previously been associated with
positive regulation of mitochondrial biogenesis in embryonic
fibroblasts and cancer cells [305, 306].
Transcription factors implicated in mitochondrial biogene-
sis are also potent inducers of the anti-inflammatory cytokines
IL-10 and IL-1Ra in both macrophages and but also liver cells
reinforcing opposite roles for oxidative metabolism and in-
flammation respectively [307]. IL-1Ra and IL-15α induction
in primary hepatocytes after fasting, exercise, glucagon, or
cAMP exposure which coincides with PGC-1α expression in
these cells further confirms the association [308]. Elevation of
IL-1Ra and IL-15α is thereby dependent on PPARα [308].
PPARα thus seems to play a dual role in mediating the anti-
inflammatory effect of oxidative metabolism: While this nu-
clear receptor acts transrepressive on the induction of NF-κB-
dependent, pro-inflammatory genes, it also promotes the ex-
pression of anti-inflammatory cytokines, at least in hepato-
cytes. Both activities in concert then shift the balance between
pro- and anti-inflammatory gene expressions. Similarly, con-
jugated linoleic acid ameliorates colitis in a model of inflam-
matory bowel disease by targeting PPARγ [309]. The treated
mice show higher PGC-1α levels while NF-κB activation and
TNFα expression are decreased [309].
A direct negative effect of any of the PGC-1 coactivators
on pro-inflammatory gene expression is somewhat unlikely,
as they have been described unequivocally as transcription
coactivators that recruit factors which facilitate transcription at
the promoter. In contrast, no corepressor activity for the PGC-
1s is known so far. Besides PPARα-dependent transactivation
and transrepression, direct interaction of PGC-1α or PGC-1β
with NF-κB family members has been reported in various cell
types. In bone marrow stromal cells, constitutive binding of
PGC-1α to p65 and p50 was decreased in the presence of
Fig. 2 Molecular mechanisms of the mutual antagonism between oxida-
tive metabolism and inflammation in skeletal muscle. a PGC-1
coactivators negatively regulate inflammation. PGC-1 coactivators are
at the crossroad of cellular respiration and inflammation as PGC-1α and
PGC-1β coactivate a set of nuclear receptors and transcription factors to
induce genes involved in oxidative metabolism. At the same time, PGC-1
coactivators interfere with inflammatory signaling at different levels.
PGC-1α and PGC-1β inhibit phosphorylation of the NF-κB subunit
p65 and thus restrain NF-κB signaling resulting in diminished expression
of pro-inflammatory cytokines. Both coactivators also induce PPARα.
This nuclear receptor acts as transrepressive on the promoters of pro-
inflammatory genes equally limiting their expression. Inversely, expres-
sion of some anti-inflammatory genes has been shown to depend on
PPARα. Whether PGC-1α and/or PGC-1β play a direct role in
coactivating PPARα on the promoters of those genes is not known. Taken
together, PGC-1 coactivators lower pro-inflammatory but induce anti-
inflammatory genes, contributing to a less inflamed environment. b
Classical NF-κB signaling inhibits PGC-1 expression. Inflammatory
stimuli like NF-κB activation reduce expression levels of both PGC-1α
and PGC-1β in various contexts. Expression of PGC-1α is driven by
CREB and MEF2, the latter being coactivated by PGC-1α in a positive
autoregulatory loop. NF-κB might constrain binding of those transcrip-
tion factors to the PGC-1α promoter; the exact mechanism of this
inhibition is however not known. Decreased PGC-1 coactivator expres-
sion in turn results in a decline of oxidative metabolism. PGC-1 , perox-
isome proliferator-activated receptor γ coactivator 1; PPARα , peroxi-
some proliferator-activated receptor α; PPRE , PPAR response element;
MEF2 , myocyte enhancer factor 2; CREB , cAMP response element
binding protein; CRE , cAMP response element
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PPARγ ligands leading to the hypothesis that PGC-1α is a
shared coactivator that NF-κB and PPARγ compete for [310].
In hepatocytes, free fatty acids induce a p50–PGC-1α inter-
action and binding of this complex to the IL-10 promoter
however with uncertain results concerning the role of PGC-
1α in regard to coactivator or corepressor activity at this site
[311]. In cardiomyocytes, binding of PGC-1α to p65 that
increased upon TNFα exposure was detected [312]. The
authors propose that p65 inhibits PGC-1α activity leading to
a drop in PDK4 and subsequently higher glucose oxidation
rates [312]. This would fit the model of NF-κB-dependent
blockade of oxidative metabolism; some ambiguities
concerning the exact mechanism however remain to be un-
covered. In skeletal muscle cells, no direct interaction of p65
or any other NF-κB family member and PGC-1α or PGC-1β
has been found.
PGC-1α may also interfere with upstream NF-κB signal-
ing. An induction of IκBα has been observed in quadriceps of
whole body PGC-1α transgenic mice in vivo but not in vitro
while Bcl3 interacts with PGC-1α synergistically to
coactivate ERRα and PPARα in cardiomyocytes [313, 314].
The reciprocity of oxidative metabolism and inflammatory
signaling may thus extend beyond the antithetic roles of
PGC-1 and NF-κB at the transcription activation level and
could involve mechanisms like cofactor competition and up-
regulation of phosphatases. The molecular details of such
processes however remain to be investigated in future studies.
Functionally, it is clear that inflammation in WAT substan-
tially contributes to the development of insulin resistance
under conditions of overfeeding with detrimental crosstalk
between immune and fat cells (see above). Cues that this
mechanism might also be in place in skeletal muscle derive
from myeloid deletion studies where silencing of the pro-
inflammatory genes JNK1, or IKKβ, in the hematopoietic
compartment or depletion of Cd11c+ cells increased insulin-
stimulated glucose disposal (which correlates to muscle insu-
lin sensitivity) under high fat diet feeding conditions whereas
hematopoietic PPARγ deletion had the opposite effect [231,
232, 242, 243]. M1 macrophage polarization thus seems to be
associated with muscle insulin resistance while M2 polariza-
tion is linked to muscle insulin sensitivity. Accordingly, an
accumulation of M1 macrophages in obese rodents and
humans has been described, and pro-inflammatory macro-
phage markers within skeletal muscle correlate with poor
glycemic control in diabetic patients whereas anti-
inflammatory markers correlate with improved parameters in
this setting [315, 316]. The model proposed here therefore
implies that, in the insulin-sensitive state, M2 macrophages
are the predominant phenotype in skeletal muscle (Fig. 3).
Endurance training, which increases PGC-1α in the muscle
cells, leads to the release of myokines that further mediate the
anti-inflammatory effects of exercise, e.g., downregulation of
certain TLRs on monocytes. In the ensuing anti-inflammatory
environment, macrophages would remain polarized in an
alternative activation state and retroact on myocytes through
the release of anti-inflammatory factors that favor the mainte-
nance of insulin sensitivity (Fig. 3). Indeed, a single bout of
exercise has recently been shown to increase insulin
Fig. 3 Potential crosstalk of skeletal muscle and the immune system. In
the trained state, skeletal muscle is insulin-sensitive, and PGC-1α levels
are chronically increased. Muscle contraction leads to the release of
myokines, which mediate many of the beneficial effect of exercise both
locally and systemically. Analogous to the events in fat tissue of lean
animals and humans, exposure of muscle-resident macrophages to these
myokines could polarize them towards an anti-inflammatory M2 pheno-
type. These M2 macrophages in turn further secrete anti-inflammatory
factors that help to maintain skeletal muscle in an insulin sensitive state.
On the other side of the spectrum, PGC-1α and PGC-1β are chronically
lowered in skeletal muscle of inactive/obese/diabetic animals or patients.
The release of pro-inflammatory factors from this insulin resistant muscle
tissue presumably drives polarization of muscle-resident macrophages
towards a pro-inflammatoryM1 phenotype.M1macrophages themselves
release more pro-inflammatory cytokines, which negatively act back onto
the muscle contributing to deterioration of muscle contractile and meta-
bolic function. In macrophages, PGC-1β has been shown to be required
for M2 macrophage activation and PGC-1α seems to be involved in this
process at least in some contexts while production of reactive oxygen
species typical for M1 macrophage activation is only possible in the
absence of PGC-1α. A comprehensive understanding of the regulation
of both coactivators in different macrophage activation states is
however still missing. PGC-1 , peroxisome proliferator-activated
receptor γ coactivator 1; M1 , classically activated, pro-inflamma-
tory macrophage; M2 , alternatively activated, anti-inflammatory or
regulatory macrophage
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sensitivity in murine skeletal muscle and entail a concomitant
accumulation of M2 macrophages [317]. If the balance be-
tween muscle cells and M2 macrophages is lost, e.g., in the
etiology of diabetes, a vicious cycle would commence ulti-
mately resulting in insulin resistance in an inflamed environ-
ment. This involves a switch to M1 macrophages, the secre-
tion of pro-inflammatory cytokines by both classically acti-
vated macrophages and muscle cells, worsening insulin sen-
sitivity on one hand and promoting inflammation on the other
hand concomitant with a decrease in muscle oxidative capac-
ity and PGC-1 coactivator levels (Fig. 3). The antagonism
between oxidative metabolism and inflammatory signaling
would thus not only provide an attractive explanation for the
different states of muscle cells in healthy and obese subjects
but is further extended to the macrophage phenotypes. High
PGC-1α levels in skeletal muscle and high PGC-1β levels in
M2macrophages would hereby correspond to the trained state
while downregulation of PGC-1 coactivators in both skeletal
muscle and macrophages would translate into an insulin-
resistant, pro-inflammatory environment in inactive, obese
patients (Fig. 3). Detailed evidence for such a myocyte–mac-
rophage crosstalk remains to be provided.
In muscle diseases, such a model would also be feasible
because ectopic expression of PGC-1α ameliorated fiber in-
tegrity and function, for example in DMD, sarcopenia, a
mitochondrial myopathy and denervation-induced fiber atro-
phy [100, 101, 140, 143]. Reducing the inflammatory reaction
in these conditions likely explains at least a part of the bene-
ficial PGC-1α effect as other strategies to counteract inflam-
mation have proven useful e.g. in DMD [101, 265, 266].
Conversely, endurance training that fosters PGC-1α expres-
sion protects against fiber damage, muscle inflammation and
soreness.
Taken together, muscle cells take active part in immune
reactions and are thus able to influence immune cells, e.g., in
their activation state. The complex interplay between those
cell types is only incompletely understood to date, and further
studies are needed to elucidate the molecular mechanisms
underlying this crosstalk. The antagonism between PGC-1
coactivators and inflammatory processes should thereby re-
ceive special attention as an imbalance is associated with
metabolic and musculoskeletal diseases.
Conclusion
Metabolism and inflammation used to be considered as two
completely independent processes in the body. In the past
decade, it has become clear that both are tightly linked at
multiple levels, which is particularly evident in cases where
homeostasis is lost like nutritional overload. The dysregula-
tion of metabolism is associated with an inflammatory reac-
tion in different organs that significantly contributes to the
development of insulin resistance while in the opposite,
healthy state, an anti-inflammatory environment prevails.
We have focused here on this interaction in skeletal muscle,
which is both metabolically and immunologically active. One
of the nodal points in this context seems the crosstalk of
oxidative metabolism through the PGC-1 coactivators and
NF-κB signaling that mutually suppress each other. It will
be of prime interest to define this relationship in greater detail
in the future and take pathological muscle conditions into
account. This would pave the way for treatment strategies
aimed not only at bringing back metabolic balance but also
at halting inflammation to improve muscle structure and
function.
Although no specific activators of PGC-1α or PGC-1β are
available at the moment, exercise induces PGC-1α in skeletal
muscle and training has been shown to counteract diseases
with sterile inflammation like diabetes and neurodegeneration.
Exercise capacity is furthermore a strong predictor of all-cause
mortality while a sedentary lifestyle is a major risk factor for
chronic diseases. Developing training regimes that optimally
target an induction of oxidative metabolism and concomitant-
ly block inflammation is a promising route to take as this
would improve both the metabolic and the immune dysfunc-
tion very likely without major side effects.
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